@article{1c013ac5818f458589380f1b751354a7,
title = "Phase I study of single-agent CC-292, a highly selective bruton{\textquoteright}s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia",
keywords = "BTK inhibitors, CC-292, Chronic lymphocytic leukemia, Refractory, Relapsed, Single-agent, Small lymphocytic lymphoma",
author = "Brown, {Jennifer R.} and Harb, {Wael A.} and Hill, {Brian T.} and Janice Gabrilove and Sharman, {Jeff P.} and Schreeder, {Marshall T.} and Barr, {Paul M.} and Foran, {James M.} and Miller, {Thomas P.} and Burger, {Jan A.} and Kelly, {Kevin R.} and Daruka Mahadevan and Shuo Ma and Yan Li and Pierce, {Daniel W.} and Evelyn Barnett and Jeffrey Marine and Monika Miranda and Ada Azaryan and Xujie Yu and Pilar Nava-Parada and Jay Mei and Kipps, {Thomas J.}",
year = "2016",
doi = "10.3324/haematol.2015.140806",
language = "English (US)",
volume = "101",
pages = "e295--e298",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",
}